Mistelihoidon näyttö kliinisissä tutkimuksissa
Eloonjäämisaika
Wode, K., Kienle, G. S., Björ, O., Fransson, P., Sharp, L., Elander, N. O., Bernhardson, B.-M., Johansson, B., Ardnor, C. E., Scheibling, U., Nordberg, J. H., & Henriksson, R. (2024). Mistletoe Extract in Patients With Advanced Pancreatic Cancer. Dtsch Arztebl International, 121(11), 347-354. https://www.aerzteblatt.de/int/article.asp?id=239558
Hofinger, J., Kaesmann, L., Buentzel, J., Scharpenberg, M., & Huebner, J. (2024). Systematic assessment of the influence of quality of studies on mistletoe in cancer care on the results of a meta-analysis on overall survival. J Cancer Res Clin Oncol, 150(4), 219. https://doi.org/10.1007/s00432-024-05742-1
Ostermann T, Appelbaum S, Poier D, Boehm K, Raak C and Büssing A. A Systematic Review and Meta-Analysis on the Survival of Cancer Patients Treated with a Fermented Viscum album L. Extract (Iscador): An Update of Findings. Complement Med Res. 2020 Jan 10:1-12. doi: 10.1159/000505202.
Kts. lisätietoja julkaisijan sivuilta
Reynel M, Villegas Y, Werthmann PG, Kiene and Kienle GS. Long-term survival of a patient with an inoperable thymic neuroendocrine tumor stage IIIa under sole treatment with Viscum album extract
A CARE compliant clinical case report. Medicine (Baltimore). 2020 Jan; 99(5): e18990. Published online 2020 Jan 31. doi: 10.1097/MD.0000000000018990
Thronicke A, Matthes B, von Trott P, Schad F & Grah C. Overall Survival of Non-metastasized NSCLC Patients Treated With Add-On Viscum album L. Integr Cancer Ther. 2020; doi: 10.1177/1534735420940384
Schad F, Thronicke A, Steele ML, Merkle A, Matthes B, Grah C and Matthes H. Overall survival of stage IV non-small cell lung cancer patients treated with Viscum album L. in addition to chemotherapy, a real-world observational multicenter analysis. PLoS One, 2018;13:e0203058. DOI: 10.1371/journal.pone.0203058
Axtner J, Steele M, Kroz M, Spahn G, Matthes H and Schad F. Health services research of integrative oncology in palliative care of patients with advanced pancreatic cancer. BMC Cancer, 2016;16:579. DOI: 10.1186/s12885-016-2594-5
Tröger W, Galun D, Reif M, Schumann A, Stankovic N and Milicevic M. Viscum album [L.] extract therapy in patients with locally advanced or metastatic pancreatic cancer. A randomised clinical trial on overall survival. European Journal of Cancer, 2013;49:3788-3797. DOI: 10.1016/j.ejca.2013.06.043
Ostermann T and Büssing A. Retrolective studies on the survival of cancer patients treated with mistletoe extracts: a meta-analysis. Explore (NY) 2012;8:277-281.
Ziegler R and Grossarth-Maticek R. Individual Patient Data Meta-analysis of Survival and Psychosomatic Self-regulation from Published Prospective Controlled Cohort Studies for Long-term Therapy of Breast Cancer Patients with a Mistletoe Preparation (Iscador). Evid Based Complement Alternat Med, 2010;7:157-166. DOI: 10.1093/ecam/nen025
Matthes H, Friedel WE, Bock PR and Zaenker KS. Molecular mistletoe therapy: friend or foe in established anti-tumor protocols? A multicenter, controlled, retrospective pharmaco-epidemiological study in pancreas cancer. Curr Mol Med, 2010;10:430-439. DOI: 10.2174/156652410791317057
Ostermann T, Raak C and Bussing A. Survival of cancer patients treated with mistletoe extract (Iscador): a systematic literature review. BMC Cancer, 2009;9:451. DOI: 10.1186/1471-2407-9-451
Friedel WE, Matthes H, Bock PR and Zaenker KS. Systematic evaluation of the clinical effects of supportive mistletoe treatment within chemo- and/or radiotherapy protocols and long-term mistletoe application in nonmetastatic colorectal carcinoma: multicenter, controlled, observational cohort study. J Soc Integr Oncol 2009;7:137-145
Grossarth-Maticek R and Ziegler R. Prospective Controlled Cohort Studies on Long-Term Therapy of Breast Cancer Patients with a Mistletoe Preparation (Iscador®). Forschende Komplementärmedizin, 2006;13:285-292. DOI: 10.1159/000095378
Augustin M, Bock PR, Hanisch J, Karasmann M and Schneider B. Safety and efficacy of the long-term adjuvant treatment of primary intermediate- to high-risk malignant melanoma (UICC/AJCC stage II and III) with a standardized fermented European mistletoe (Viscum album L.) extract. Arzneimittelforschung, 2005;55:38-49. DOI: 10.1055/s-0031-1296823
Bock PR, Friedel WE, Hanisch J, Karasmann M and Schneider B. [Efficacy and safety of long-term complementary treatment with standardized European mistletoe extract (Viscum album L.) in addition to the conventional adjuvant oncologic therapy in patients with primary non-metastasized mammary carcinoma. Results of a multi-center, comparative, epidemiological cohort study in Germany and Switzerland]. Arzneimittelforschung, 2004;54:456-466. DOI: 10.1055/s-0031-1296999
Grossarth-Maticek R, Kiene H, Baumgartner S, Ziegler R. Synergieeffekte von Selbstregulation und Misteltherapie (Iscador) auf die Uberlebenszeit bei Krebspatienten. Schweiz Zschr Ganzheitsmedizin. 2004; 16(2): 81–9.